EIDX News and Press, Eidos Therapeutics Inc. From 10/14/19

Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that...

Over the past three months, the Nasdaq Biotechnology index has tumbled around 9.5% and industrywide worries have pressured share prices of some companies that didn't deserve a market beatdown. Axsome Therapeutics (NASDAQ: AXSM) , BridgeBio Pharma (NASDAQ: BBIO) , and Kodiak Sciences (...

SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced that an interim analysis of its ong...

SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3 rd at 3:00 p.m. EDT in New York, NY. A live audio webcast of the presen...

The world of biotech investing can be tricky. And that's particularly true for small-cap stocks in the biotech sector. These companies often have terrific science, but no profits and little if any revenues. And yet there are outstanding opportunities in this sector for investors who know what ...

Advises Stockholders Take No Action at this Time Eidos Therapeutics, Inc. (Nasdaq:EIDX) (“Eidos”) announced today that the Special Committee of its Board of Directors (the “Special Committee”) unanimously rejected the non-binding proposal dated August 8, 201...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking Ole Andreas Halvorsen's Viking Global...

Alexion Pharmaceuticals (NASDAQ: ALXN ) and BridgeBio Pharma's (NASDAQ: BBIO ) subsidiary Eidos Therapeutics (NASDAQ: EIDX ) have announced an agreement that grants Alexion an exclusive license to develop and commercialize AG10 in Japan. More news on: Alexion Pharmaceuticals, I...

Shares of BridgeBio Pharma ( BBIO ) are currently up 75% from IPO pricing of $17 per share in late June (a bullish sign). To be fair, shares actually opened for trading at roughly $30 and so have relatively flat performance for investors who bought on the open market. I was originally attr...

In recent years, mountains of institutional capital have flowed into hundreds of biotech start-ups and so many of them have gone public that it's impossible for anyone with a day job to keep track of them all. I'll let you in on a little secret. Those of us paid to know things about the biophar...